BofA Securities Starts Spring Works Therapeutics (SWTX) at Buy on Rare Tumor Drug Differentiator
Tweet Send to a Friend
(Updated - December 1, 2022 9:12 AM EST)
BofA Securities analyst Alec Stranahan initiates coverage on Spring Works Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA Securities analyst Alec Stranahan initiates coverage on Spring Works Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
